Literature DB >> 32181877

Development and validation of a five-gene model to predict postoperative brain metastasis in operable lung adenocarcinoma.

Fangqiu Fu1,2,3,4, Yang Zhang1,2,3,4, Zhendong Gao1,2,3,4, Yue Zhao1,2,3,4, Zhexu Wen1,2,3,4, Han Han1,2,3,4, Yuan Li4,5, Haiquan Chen1,2,3,4.   

Abstract

One of the most common sites of extra-thoracic distant metastasis of nonsmall-cell lung cancer is the brain. Our study was performed to discover genes associated with postoperative brain metastasis in operable lung adenocarcinoma (LUAD). RNA seq was performed in specimens of primary LUAD from seven patients with brain metastases and 45 patients without recurrence. Immunohistochemical (IHC) assays of the differentially expressed genes were conducted in 272 surgical-resected LUAD specimens. LASSO Cox regression was used to filter genes related to brain metastasis and construct brain metastasis score (BMS). GSE31210 and GSE50081 were used as validation datasets of the model. Gene Set Enrichment Analysis was performed in patients stratified by risk of brain metastasis in the TCGA database. Through the initial screening, eight genes (CDK1, KPNA2, KIF11, ASPM, CEP55, HJURP, TYMS and TTK) were selected for IHC analyses. The BMS based on protein expression levels of five genes (TYMS, CDK1, HJURP, CEP55 and KIF11) was highly predictive of brain metastasis in our cohort (12-month AUC: 0.791, 36-month AUC: 0.766, 60-month AUC: 0.812). The validation of BMS on overall survival of GSE31210 and GSE50081 also showed excellent predictive value (GSE31210, 12-month AUC: 0.682, 36-month AUC: 0.713, 60-month AUC: 0.762; GSE50081, 12-month AUC: 0.706, 36-month AUC: 0.700, 60-month AUC: 0.724). Further analyses showed high BMS was associated with pathways of cell cycle and DNA repair. A five-gene predictive model exhibits potential clinical utility for the prediction of postoperative brain metastasis and the individual management of patients with LUAD after radical resection.
© 2020 UICC.

Entities:  

Keywords:  RNA-seq; brain metastasis; immunohistochemical assays; lung adenocarcinoma; predictive models

Year:  2020        PMID: 32181877     DOI: 10.1002/ijc.32981

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  KIF11 Serves as an Independent Prognostic Factor and Therapeutic Target for Patients With Lung Adenocarcinoma.

Authors:  Zhaodong Li; Bingxin Yu; Fangyuan Qi; Fan Li
Journal:  Front Oncol       Date:  2021-04-23       Impact factor: 6.244

2.  Integrative Expression and Prognosis Analysis of DHX37 in Human Cancers by Data Mining.

Authors:  Kang Huang; Tudi Pang; Changjun Tong; Houqing Chen; Yupeng Nie; Jiayi Wu; Yandong Zhang; Ganghong Chen; Wei Zhou; Dazhi Yang
Journal:  Biomed Res Int       Date:  2021-01-02       Impact factor: 3.411

3.  Integrated single-cell RNA sequencing analysis reveals distinct cellular and transcriptional modules associated with survival in lung cancer.

Authors:  Li Zhang; Yiming Zhang; Chengdi Wang; Ying Yang; Yinyun Ni; Zhoufeng Wang; Tingting Song; Menglin Yao; Zhiqiang Liu; Ningning Chao; Yongfeng Yang; Jun Shao; Zhidan Li; Ran Zhou; Li Chen; Dan Zhang; Yuancun Zhao; Wei Liu; Yupeng Li; Ping He; Jing-Wen Lin; Yuan Wang; Kang Zhang; Lu Chen; Weimin Li
Journal:  Signal Transduct Target Ther       Date:  2022-01-14

4.  miR-423-3p activates FAK signaling pathway to drive EMT process and tumor growth in lung adenocarcinoma through targeting CYBRD1.

Authors:  Jun Ma; Wuhao Huang; Chaonan Zhu; Xiaoyan Sun; Qiang Zhang; Lianmin Zhang; Qi Qi; Xiaoming Bai; Yun Feng; Changli Wang
Journal:  J Clin Lab Anal       Date:  2021-10-29       Impact factor: 2.352

5.  MicroRNA-140-3p represses the proliferation, migration, invasion and angiogenesis of lung adenocarcinoma cells via targeting TYMS (thymidylate synthetase).

Authors:  Shanzhi Wan; Zhimin Liu; Yang Chen; Zhitao Mai; Mingming Jiang; Qingguo Di; Baohua Sun
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 6.  Emerging Biomarkers for Diagnosis, Prevention and Treatment of Brain Metastases-From Biology to Clinical Utility.

Authors:  Priyakshi Kalita-de Croft; Vaibhavi Joshi; Jodi M Saunus; Sunil R Lakhani
Journal:  Diseases       Date:  2022-02-03

Review 7.  [Research Progress on Risk Factors of Brain Metastasis in Non-small Cell Lung Cancer].

Authors:  Shuang Sun; Yu Men; Zhouguang Hui
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-03-20

8.  PTS is activated by ATF4 and promotes lung adenocarcinoma development via the Wnt pathway.

Authors:  Wei Ma; Chao Wang; Ruzhen Li; Zhaohui Han; Yuanzhu Jiang; Xiangwei Zhang; Duilio Divisi; Enrico Capobianco; Lin Zhang; Wei Dong
Journal:  Transl Lung Cancer Res       Date:  2022-09

9.  Exonuclease 1 (EXO1) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Lung Adenocarcinoma.

Authors:  Chang-Shuai Zhou; Ming-Tao Feng; Xin Chen; Yang Gao; Lei Chen; Liang-Dong Li; De-Heng Li; Yi-Qun Cao
Journal:  Onco Targets Ther       Date:  2021-02-15       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.